Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BI 1015550 drug interaction study with itraconazole in healthy volunteers
NCT03403439Phase 1Completed
- Sponsor
- Boehringer Ingelheim
- Start
- May 2018
- Primary completion
- Jul 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of nerandomilast, sponsored by Boehringer Ingelheim. Primary endpoints: Area Under the Concentration-time Curve of BI 1015550 in Plasma Over the Time Interval From 0 to 119 Hours and Maximum Measured Concentration of the BI 1015550 in Plasma at 215 hours. Started May 2018; status: completed.
02
Drugs
nerandomilast
Beyond the preview
Go deeper on NCT03403439.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03403439.